Capstone Investment Advisors
REVBW icon

Capstone Investment Advisors’s Revelation Biosciences Warrant REVBW Stock Holding History

Capstone Investment Advisors’s Portfolio REVBW Stock Details REVBW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-91,833
Closed -$7K – 1746
2022
Q2 		$7K Hold
91,833
– – ﹤0.01% 1701
2022
Q1 		$12K Hold
91,833
– – ﹤0.01% 1973
2021
Q4 		$62K Hold
91,833
– – ﹤0.01% 1656
2021
Q3 		$57K Buy
+91,833
New +$55.7K ﹤0.01% 1840

Other funds holding REVBW

OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Wolverine Asset Management
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Capstone Investment Advisors's REVBW Position: Q3 2022 in Review

Capstone Investment Advisors sold out of Revelation Biosciences Warrant (REVBW) in Q3 2022, closing a stake of 91,833 shares — an estimated $7K sold.

Capstone Investment Advisors first reported a position in REVBW in Q3 2021 and held it in 4 quarters. The position peaked at $62K in Q4 2021. 12 funds tracked by Wall St. Rank hold REVBW as of Q3 2022.

  • Capstone Investment Advisors reported no remaining Revelation Biosciences Warrant position as of Q3 2022 after selling out during the quarter.
  • Capstone Investment Advisors sold 91,833 Revelation Biosciences Warrant shares in Q3 2022, an estimated $7K.
  • Capstone Investment Advisors first reported a position in Revelation Biosciences Warrant in Q3 2021 and held it in 4 quarters.
  • Capstone Investment Advisors's Revelation Biosciences Warrant position peaked at $62K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences Warrant as of Q3 2022.

Based on Capstone Investment Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.